Erin Harris
Click here to email Erin.
Erin Harris is chief editor of Cell & Gene and a contributing editor to Life Science Leader magazine. She studied English and psychology at Lafayette College and has 20+ years of experience in B2B publishing. Erin spent 10 years covering and reporting on the adoption of information technology from a B2B perspective. She’s written on technology topics ranging from Big Data and analytics to security and e-commerce. In each case, her reporting centered on innovations that improved operational efficiencies, fostered interdepartmental collaboration, or enhanced supply chains. Currently, she writes actionable information for professionals involved in the development and commercialization of cell and gene therapies. She covers the entire product lifecycle from basic research to commercialization. Erin has interviewed executives from Fortune 500 as well as startups. She has moderated panel discussions and has spoken at numerous industry events from large conferences to niche forums.
ARTICLES BY ERIN HARRIS
-
![26_05_CGL]( "CGT Manufacturing Shifts From Capacity To Strategy")
CGT Manufacturing Shifts From Capacity To Strategy5/21/2026As manufacturing overcapacity reshapes the CGT landscape, success now depends less on access to capacity and more on strategic alignment across development, regulatory readiness, and long-term commercialization.
-
![regulations, rules, guidelines, laws, compliance and standards, compliance-GettyImages-2186729096]( "Dr. Peter Marks On Why Gene Therapy May Need A New Regulatory Playbook")
Dr. Peter Marks On Why Gene Therapy May Need A New Regulatory Playbook5/13/2026At the 2026 @Philly Cell and Gene Therapy Annual Conference, Dr. Peter Marks highlighted how gene therapy science is surging ahead and called for smarter regulatory evolution to unlock treatments for thousands of rare disease patients.
-
![Sense of hearing, auditory perception-GettyImages-2159129607]( "Regeneron Advances In Vivo Gene Therapy For Hearing Loss")
Regeneron Advances In Vivo Gene Therapy For Hearing Loss5/1/2026Regeneron’s Otarmeni marks a major CGT milestone, showing that in vivo gene therapy can restore hearing in OTOF-related deafness while expanding the field’s clinical and delivery possibilities.
-
![Diabetes Type 1, application new technology in future medicine-GettyImages-837092948]( "Sana, Mayo Clinic Advance A New Model For Cell Therapy Delivery In T1D")
Sana, Mayo Clinic Advance A New Model For Cell Therapy Delivery In T1D4/27/2026Sana Biotechnology and Mayo Clinic are partnering to standardize delivery of a one-time hypoimmune cell therapy, aiming to scale access and redefine care for type 1 diabetes.
-
![woman scientist with protective goggle and gloves-GettyImages-918825222]( "Reprogramming T-Cell Access To Solid Tumors Through Improved Trafficking And Entry")
Reprogramming T-Cell Access To Solid Tumors Through Improved Trafficking And Entry4/17/2026Here's why trafficking and entry remain key barriers to CAR T success in solid tumors.
-
![CAR T cells-GettyImages-2243155532]( "Target Selection Drives The Future Of CAR T Therapy In Solid Tumors")
Target Selection Drives The Future Of CAR T Therapy In Solid Tumors4/13/2026Target selection is the defining challenge in CAR T therapy for solid tumors, shaping safety, efficacy, and the field’s path forward.
-
![Car-T cell attacking cancer cell-GettyImages-2252478724]( "Mitigating Challenges In Solid Tumor Delivery")
Mitigating Challenges In Solid Tumor Delivery4/3/2026CAR T-cell therapy is advancing in solid tumors by improving target selection, trafficking, tumor-microenvironment resistance, and long-term function, but major biological barriers still require combined solutions.
-
![Female scientist microscope-GettyImages-1453524892]( "Ensuring Quality Of CGT Materials")
Ensuring Quality Of CGT Materials3/24/2026Here's why strong material selection, risk-based controls, and early analytics are critical for successful CGT development.
-
![medical chart, healthcare, medicine-GettyImages-2217159653]( "Building Harmonized Real‑World Data In Oncology")
Building Harmonized Real‑World Data In Oncology3/13/2026Experts at PMWC 2026 emphasized that regulatory‑grade real‑world data in oncology will require prospectively collected, harmonized datasets that integrate multimodal clinical information.
-
![T-Cells Work to Fight Cancer, Immunotherapy, CAR T-cell therapy-GettyImages-1317697233]( "The In Vivo Cell Therapy Shift On Display At PMWC 2026")
The In Vivo Cell Therapy Shift On Display At PMWC 20263/10/2026At PMWC 2026 in Santa Clara, we saw how in vivo CAR T and MRD‑guided strategies could reshape cell therapy by moving curative intent earlier while balancing bold innovation with practical scalability.
